Janet Reiser, MD
Gastroenterology · Scottsdale, AZNPI 1942270947
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,965 of the $5,796 with a category attached, or 85.7%. 26 manufacturers reported payments, led by AbbVie at 31.0% of the total. Reporting peaked in 2019 at $1,902 and has fallen 75.6% since, to $465 in 2025.
Across 174 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Romark Laboratories, LC$824
- Johnson & Johnson$457
- Regeneron Healthcare Solutions, Inc.$388
- Boston Scientific$358
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$342
- plus $2K from 20 others
Across 79 payments — averaging $3887.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$289K
- Bausch Health US, LLC$18K
What the payments were for
- Food & beverage$4,96586%
- Education$70%
- Ownership interest$82414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,794 |
| Romark Laboratories, LC | 1 | $824 |
| Johnson & Johnson(2 entities) | 13 | $457 |
| Regeneron Healthcare Solutions, Inc. | 11 | $388 |
| Boston Scientific | 5 | $358 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $342 |
| Pfizer | 10 | $273 |
| E.r. Squibb & Sons, L.L.C. | 2 | $245 |
| Bristol Myers Squibb | 8 | $148 |
| Madrigal Pharmaceuticals | 1 | $144 |
| Merck | 2 | $120 |
| Dova Pharmaceuticals | 1 | $113 |
| Gilead | 4 | $113 |
| Sanofi | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Nestle Healthcare Nutrition Inc. | 5 | $77 |
| Ironwood Pharmaceuticals, Inc | 4 | $70 |
| Medtronic | 1 | $55 |
| Axonics, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| QOL Medical, LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
| Braintree Laboratories, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,796 in reported general payments places this provider in the 60th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 14 | $61,743 |
| CreonLipase/Protease/Amylase | 12 | $36,787 |
| LinzessLinaclotide | 27 | $32,581 |
| Mesalamine | 32 | $18,137 |
| Mesalamine ErMesalamine | 11 | $2,494 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 88 | $1,822 |
| Famotidine | 119 | $1,447 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 22 | $1,422 |
| Sucralfate | 26 | $1,376 |
| Pantoprazole Sodium | 88 | $891 |
| Balsalazide Disodium | 12 | $884 |
| CholestyramineCholestyramine (With Sugar) | 11 | $692 |
| Sulfasalazine | 16 | $532 |
| Omeprazole | 35 | $331 |
| Ondansetron OdtOndansetron | 17 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,794 | $69,36839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Scottsdale
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
- Woong KimScottsdale$138K
- Adam HarrisScottsdale$127K
- Anil SeetharamScottsdale$111K
- Amar ThosaniScottsdale$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.